July 24 evening, Yi Chiao Shenzhou (SZ301047, share price 121.19 yuan, market value 15.66 billion yuan) disclosed that the company's board of directors in recently received the company's R & D director and the core technical staff of the written resignation report of Yang Jiahui, due to personal reasons, Yang Jiahui applied for resignation of the company's R & D director position. After the resignation, Yang Jiahui no longer holds any position in the company.
According to the relevant provisions, Yang Jiahui's resignation report will take effect from the date of delivery to the Board of Directors. Yang Jiahui responsible for the work has been completed the handover, personnel changes will not affect the normal work of the company, will not have a negative impact on the production and operation of the company.
As of the date of disclosure of this announcement, Yang Jiahui indirectly holds 143,700 shares of the company's shares through the shareholding platform. Meanwhile, Yang Jiahui's pre-tax compensation from the company totaled $779,200, according to Yiqiao Shenzhou's 2021 financial report.
It is reported that Yang Jiahui, female, born in 1980, Chinese nationality, no permanent residence abroad. graduated from Tufts University in 2010, majoring in molecular biology and genetics, with a Ph.D. From June 2010 to December 2016, she served as Divine Cells Limited protein From January 2017 to present, he has been the head of protein product strategy and director of research and development of Yiciao Limited and Yiciao Technology.
In addition, according to the 2021 financial report, as of December 31, 2021, the company has 495 employees on board, of which, 157 employees with master's and doctoral degrees, and 15 employees represented by Dr. Yang Jiahui, head of research and development, have been selected in 2021 as the leading talents, highly skilled talents and outstanding talents of the Beijing Economic-Technological Development Area, respectively.
Yiqiao Shenzhou said on July 18 in the interactive platform to answer investor questions, Suzhou subsidiary is expected to be put into operation within this year. The main business of the Suzhou subsidiary is biotechnology research and development and biosafety testing technology services. All aspects of the company will quickly promote the construction of the Suzhou project, and strive to build a high level and high standard of R & D and testing laboratories, to provide support services for southern pharmaceutical companies nearby.
Yiqiao Shenzhou said on the interactive platform on July 13 that the company, as one of the mainstream suppliers of recombinant viral proteins in the world, has successfully developed recombinant A29 proteins expressed by monkeypox 29L gene and recombinant L1R proteins expressed by L1R gene by designing according to the released monkeypox virus gene sequences, and other important target antigens, A33R, A35R, and B21R, are under development. In terms of new coronaviruses, the company has independently developed the recombinant A29 protein. As for new coronavirus, the company has independently developed recombinant protein of BA.4 and BA.5, pseudovirus and other reagent products. Up to now, the company's production and operation are all normal, and the production capacity can meet customer demand.
Yi Chiao Shenzhou released a quarterly performance announcement on the evening of April 28, said the first quarter of 2022 revenue of about 176 million yuan, a year-on-year decrease of 61.49%; net profit attributable to shareholders of listed companies of about 114 million yuan, a year-on-year decrease of 65.61%; basic earnings per share of 1.6801 yuan, a year-on-year decrease of 74.21%.
According to the official website of Yiqiao Shenzhou, the company was listed on the GEM board of the Shenzhen Stock Exchange on August 16, 2021, with the number of shares issued publicly at 17 million, and the issuance price at 292.92 yuan per share. As a national high-tech enterprise, the company is a biotechnology company mainly engaged in the research and development, production and sales of biological reagents and the provision of technical services, the main business includes recombinant proteins, antibodies, genes and media and other products, as well as recombinant proteins, antibodies, the development and bio-analysis and testing and other services, and also provides preclinical scale production services for monoclonal antibody candidates for pharmaceutical companies or biotechnology companies.
For more real-time financial news, please follow us.